Buy & Sell Ally Financial Inc (ALLY) – Ally Financial Inc Price Today
Aura AI Summary
Key Stats
- $12.98BMarket Cap
- FinancialsSector
- -11.77%3M Drawdown
- -Enterprise Value
- 2.83%Dividend Yield
- 66 daysTypical Hold Time
Ally Financial Inc (ALLY) is currently valued at a market capitalization of $12.98B. Over the past 52 weeks, Ally Financial Inc has traded between a low of $33.58 and a high of $47.06, highlighting its annual price range. Over the past three months, Ally Financial Inc has recorded a drawdown of -11.77%, reflecting recent price volatility. Ally Financial Inc offers a dividend yield of 2.83%, with the most recent dividend of $0.30 paid on 01 May 26. On average, investors hold Ally Financial Inc for approximately 66 days, indicating typical investor behavior on the platform.
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Most Recent News
Microneedle drug delivery market to double to $14.37B by 2035, driven by pain-free therapies and vaccine tech.
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...

Akeso to present over 40 oncology studies at ASCO 2026, highlighting key bispecific antibody trials.
Akeso, Inc. announced it will present more than 40 clinical studies of its oncology portfolio at the 2026 ASCO Annual Meeting, including a Late-Breaking Abstract in the Plenary Session. Key data will focus on its bispecific antibodies cadonilimab and...

Hansa Biopharma to present positive 12-month Phase 3 kidney transplant trial results at American Transplant Congress.
Hansa Biopharma announced that its Phase 3 ConfIdeS trial results for kidney transplantation in highly sensitized patients will be presented at the American Transplant Congress on June 22, 2026. The presentation will detail 12-month outcomes, includi...
